References
- Grobusch MP, Muhlberger N, Jelinek T, Bisoffi Z, Corachan M, Harms G, et al. Imported schistosomiasis in Europe: sentinel surveillance data from TropNetEurop. J Travel Med 2003; 10: 164–9
- Vermund SH, Bradley DJ, Ruiz-Tiben E. Survival of Schistosoma mansoni in the human host: estimates from a community-based prospective study in Puerto Rico. Am J Trop Med Hyg 1983; 32: 1040–8
- Fulford AJ, Butterworth AE, Ouma JH, Sturrock RF. A statistical approach to schistosome population dynamics and estimation of the lifespan of Schistosoma mansoni in man. Parasitology 1995; 110: 307–16
- Warren KS, Mahmoud AA, Cummings P, Murphy DJ, Houser HB. Schistosoma mansoni in Yemeni in California: duration of infection, presence of disease, therapeutic management. Am J Trop Med Hyg 1974; 23: 902–9
- Harris AR, Russell RJ, Charters AD. A review of schistosomiasis in immigrants in Western Australia, demonstrating the unusual longevity of Schistosoma mansoni. Trans R Soc Trop Med Hyg 1984; 78: 385–8
- Chabasse D, Bertrand G, Leroux JP, Gauthey N, Hocquet P. Bilharziose à Schistosoma mansoni évolutive découverte 37 ans après l'infestation. Bull Soc Pathol Exot Filiales 1985; 78: 643–7
- Hornstein L, Lederer G, Schechter J, Greenberg Z, Boem R, Bilguray B, et al. Persistent Schistosoma mansoni infection in Yemeni immigrants to Israel. Isr J Med Sci 1990; 26: 386–9
- Hall SC, Kehoe EL. Case reports: prolonged survival of Schistosoma japonicum. Calif Med 1970; 113: 75–7
- Doenhoff MJ, Hassounah O, Murare H, Bain J, Lucas S. Schistosome egg granuloma: immunopathology in the cause of host protection or parasite survival?. Trans R Soc Trop Med Hyg 1986; 80: 503–14
- Hernandez HJ, Wang Y, Tzellas N, Stadecker MJ. Expression of class II, but not class I, major histocompatibility complex molecules is required for granuloma formation in infection with Schistosoma mansoni. Eur J Immunol 1997; 27: 1170–6
- N'Zoukoudi-N'Doundou MY, Dirat I, Akouala JJ, Penchenier L, Makuwa M, Rey JL. Bilharziose et infection par le virus de l'immunodeficience humaine au congo. Med Trop (Mars) 1995; 55: 249–51
- Karanja DM, Colley DG, Nahlen BL, Ouma JH, Secor WE. Studies on schistosomiasis in western Kenya: I. Evidence for immune-facilitated excretion of schistosome eggs from patients with Schistosoma mansoni and human immunodeficiency virus coinfections. Am J Trop Med Hyg 1997; 56: 515–21
- Fontanet AL, Woldemichael T, Sahlu T, van Dam GJ, Messele T, Rinke de Wit T, et al. Epidemiology of HIV and Schistosoma mansoni infections among sugar-estate residents in Ethiopia. Ann Trop Med Parasitol 2000; 94: 145–55
- Mwinzi PN, Karanja DM, Colley DG, Orago AS, Secor WE. Cellular immune responses of schistosomiasis patients are altered by human immunodeficiency virus type 1 coinfection. J Infect Dis 2001; 184: 488–96
- Mwatha JK, Kimani G, Kamau T, Mbugua GG, Ouma JH, Mumo J, et al. High levels of TNF, soluble TNF receptors, soluble ICAM-1, and IFN-gamma, but low levels of IL-5, are associated with hepatosplenic disease in human schistosomiasis. J Immunol 1998; 160: 1992–9
- Fallon PG, Dunne DW. Tolerance of mice to Schistosoma mansoni egg antigens causes elevated type 1 and diminished type 2 cytokine responses and increased mortality in acute infection. J Immunol 1999; 162: 4122–32
- Karanja DM, Boyer AE, Strand M, Colley DG, Nahlen BL, Ouma JH, et al. Studies on schistosomiasis in western Kenya: II. Efficacy of praziquantel for treatment of schistosomiasis in persons coinfected with human immunodeficiency virus 1. Am J Trop Med Hyg 1998; 59: 307–11